<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2176-6223</journal-id>
<journal-title><![CDATA[Revista Pan-Amazônica de Saúde]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Pan-Amaz Saude]]></abbrev-journal-title>
<issn>2176-6223</issn>
<publisher>
<publisher-name><![CDATA[Instituto Evandro Chagas. Secretaria de Vigilância em Saúde e Ambiente. Ministério da Saúde]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2176-62232010000300014</article-id>
<article-id pub-id-type="doi">10.5123/S2176-62232010000300014</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Soroprevalência do vírus linfotrópico de células T humanas em comunidades ribeirinhas da região nordeste do Estado do Pará, Brasil]]></article-title>
<article-title xml:lang="en"><![CDATA[Human T-lymphotropic virus seroprevalence in riparian communities in the northeastern region of Pará State, Brazil]]></article-title>
<article-title xml:lang="es"><![CDATA[Seroprevalencia del virus linfotrópico de células T humanas en comunidades ribereñas de la región nordeste del Estado de Pará, Brasil]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[Louise de Souza Canto]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[Jaqueline Helen Godinho]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[Carlos Araújo da]]></given-names>
</name>
<xref ref-type="aff" rid="A03"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Melo]]></surname>
<given-names><![CDATA[Marly de Fátima Carvalho de]]></given-names>
</name>
<xref ref-type="aff" rid="A04"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Andrade]]></surname>
<given-names><![CDATA[Marizete Lopes]]></given-names>
</name>
<xref ref-type="aff" rid="A05"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martins]]></surname>
<given-names><![CDATA[Luisa Carício]]></given-names>
</name>
<xref ref-type="aff" rid="A03"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ishikawa]]></surname>
<given-names><![CDATA[Edna Aoba Yassui]]></given-names>
</name>
<xref ref-type="aff" rid="A03"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sousa]]></surname>
<given-names><![CDATA[Maisa Silva de]]></given-names>
</name>
<xref ref-type="aff" rid="A03"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Centro Universitário do Pará Faculdade de Farmácia ]]></institution>
<addr-line><![CDATA[Belém Pará]]></addr-line>
<country>Brasil</country>
</aff>
<aff id="A02">
<institution><![CDATA[,Universidade Federal do Pará Instituto de Ciências da Saúde Faculdade de Ciências Biológicas]]></institution>
<addr-line><![CDATA[Belém Pará]]></addr-line>
<country>Brasil</country>
</aff>
<aff id="A03">
<institution><![CDATA[,Universidade Federal do Pará Núcleo de Medicina Tropical ]]></institution>
<addr-line><![CDATA[Belém Pará]]></addr-line>
<country>Brasil</country>
</aff>
<aff id="A04">
<institution><![CDATA[,Universidade Federal do Pará Instituto de Ciências da Saúde Faculdade de Farmácia]]></institution>
<addr-line><![CDATA[Belém Pará]]></addr-line>
<country>Brasil</country>
</aff>
<aff id="A05">
<institution><![CDATA[,Sociedade Bíblica do Brasil Programa Luz na Amazônia ]]></institution>
<addr-line><![CDATA[Belém Pará]]></addr-line>
<country>Brasil</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2010</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2010</year>
</pub-date>
<volume>1</volume>
<numero>3</numero>
<fpage>103</fpage>
<lpage>108</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_arttext&amp;pid=S2176-62232010000300014&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_abstract&amp;pid=S2176-62232010000300014&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_pdf&amp;pid=S2176-62232010000300014&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[O vírus-T linfotrópico humano do tipo 1 (HTLV-1) foi o primeiro retrovírus humano a ser identificado e está associado a várias doenças debilitantes. O Estado do Pará é o terceiro do Brasil com maior frequência de infecção por HTLV entre doadores de sangue. As comunidades ribeirinhas são carentes de ações de educação e assistência à saúde, pela característica de terem moradias espalhadas ao longo de furos e pela dificuldade de acesso aos centros urbanos. Este estudo objetivou investigar a infecção causada pelo HTLV em comunidades ribeirinhas do nordeste paraense, atendidas pelo Programa Luz na Amazônia, entre fevereiro de 2009 e junho de 2010. Pesquisa de anticorpos anti-HTLV-1/2 foi realizada em 175 ribeirinhos, sendo 30 (17,14%) da comunidade de São Pedro (Acará); 62 (35,43%) da comunidade do Furo do Aurá (Belém) e 83 (47,43%) de Santa Maria (Acará). Nos casos reagentes, métodos de biologia molecular foram utilizados para confirmação da infecção e identificação do tipo viral. A prevalência total do HTLV-1 foi de 1,14% (2/175), variando entre zero (0/34) em São Pedro, 1,20% (1/83) em Santa Maria e 1,61% (1/62) no Furo do Aurá. O HTLV-1 foi identificado em duas das 117 (1,71%) famílias analisadas das três comunidades. Não foi observado nenhum caso de transmissão familiar na amostra. O HTLV-2 não foi encontrado na amostra estudada. Este estudo demonstrou a ocorrência de HTLV-1 nas comunidades ribeirinhas estudadas, com frequências semelhantes às de populações urbanas, indicando a necessidade de maior investigação e ações de prevenção das doenças associadas ao vírus nessas comunidades.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[The human T-lymphotropic virus 1 (HTLV-1) was the first human retrovirus identified, and it is associated with several debilitating diseases. Pará State has the third highest frequency rate of HTLC infections among blood donors in Brazil. Its riparian communities lack educational policies and health care assistance mainly because they inhabit "furos" (Amazonian river channels) and do not have easy access to urban centers. This study aimed to investigate the infection by HTLV in riparian communities of northeastern Pará included in the Luz na Amazônia Program between February 2009 and June 2010. A total of 175 riparian individuals were selected for detection of anti-HTLV-1/2 antibodies: 30 from the São Pedro community (Municipality of Acará), 62 from the Furo do Aurá Community (Municipality of Belém), and 83 from Santa Maria (Municipality of Acará). In the HTLV-reactive individuals we used molecular methods to confirm infection and identify the viral type. HTLV-2 was not found in the study samples. The overall prevalence of HTLV-1 was 1.14% (2/1 75), ranging from zero (0/34) in São Pedro to 1.20% (1/83) in Santa Maria and 1.61 % (1/62) in Furo do Aurá. HTLV-1 was identified in two of 117 (1.35%) families from all three communities. We reported no evidence of familial transmission through testing of samples. HTLV-2 was not found in the samples tested. This study demonstrates the occurrence of HTLV-1 in the riparian communities studied, with frequency rates similar to those of urban populations, which warrants further research and actions to prevent diseases associated with HTLV in these communities.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[El virus-T linfotrópico humano del tipo 1 (HTLV-1) fue el primer retrovirus humano a ser identificado y está asociado a varias enfermedades debilitantes. El Estado de Pará es el tercero de Brasil con mayor frecuencia de la infección por HTLV entre donantes de sangre. Las comunidades ribereñas carecen de acciones de educación y asistencia a la salud, por la característica de sus viviendas, esparcidas a lo largo de los ríos y cursos de agua, y por la dificultad de acceso a los centros urbanos. Este estudio tuvo como objetivo investigar la infección causada por el HTLV en comunidades ribereñas del nordeste paraense, atendidas por el Programa Luz en la Amazonia, entre febrero de 2009 y junio de 2010. Fue realizada una investigación de anticuerpos anti-HTLV-1/2 en 175 ribereños, siendo 30 (17,14%) de la comunidad de São Pedro (Acará); 62 (35,43%) de la comunidad del Furo do Aurá (Belém) y 83 (47,43%) de Santa Maria (Acará). En los casos reactivos, se utilizaron métodos de biología molecular para confirmar la infección e identificar el tipo viral. La prevalencia total del HTLV-1 fue de 1,14% (2/175), variando entre cero (0/34) en São Pedro, 1,20% (1/83) en Santa Maria y 1,61% (1/62) en el Furo do Aurá. El HTLV-1 fue identificado en dos de las 117 (1,71%) familias analizadas de las tres comunidades. No se observó ningún caso de transmisión familiar en la muestra. El HTLV-2 no fue hallado en la muestra estudiada. Este estudio demostró la ocurrencia de HTLV-1 en las comunidades ribereñas estudiadas, con frecuencias similares a las de las poblaciones urbanas, indicando la necesidad de una mayor investigación y de acciones de prevención de las enfermedades asociadas al virus en esas comunidades.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Deltaretrovirus]]></kwd>
<kwd lng="pt"><![CDATA[Estudos Transversais]]></kwd>
<kwd lng="pt"><![CDATA[Estudos Soroepidemiológicos]]></kwd>
<kwd lng="pt"><![CDATA[ELISA]]></kwd>
<kwd lng="en"><![CDATA[Deltaretrovirus]]></kwd>
<kwd lng="en"><![CDATA[Cross-Sectional Studies]]></kwd>
<kwd lng="en"><![CDATA[Seroepidemiologic Studies]]></kwd>
<kwd lng="en"><![CDATA[Enzyme-Linked Immunosorbent Assay]]></kwd>
<kwd lng="es"><![CDATA[Deltaretrovirus]]></kwd>
<kwd lng="es"><![CDATA[Estudios Transversales]]></kwd>
<kwd lng="es"><![CDATA[Estudios Seroepidemiológicos]]></kwd>
<kwd lng="es"><![CDATA[Prueba ELISA]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p align="right"><font size="2" face="Verdana"><b>ARTIGO ORIGINAL | ORIGINAL ARTICLE | ART&Iacute;CULO ORIGINAL</b></font></p>     <p>&nbsp;</p>     <p><font size="2" face="Verdana"><strong><a name="topo" id="topo"></a><font size="4">Soropreval&ecirc;ncia do v&iacute;rus linfotr&oacute;pico de c&eacute;lulas T humanas em  comunidades ribeirinhas da regi&atilde;o nordeste do Estado do Par&aacute;, Brasil</font></strong></font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"> <b>Human  T-lymphotropic virus seroprevalence in riparian communities in the northeastern  region of Par&aacute; State, Brazil</b></font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"> <b>Seroprevalencia del virus linfotr&oacute;pico de  c&eacute;lulas T humanas en comunidades ribere&ntilde;as de la regi&oacute;n nordeste del Estado de Par&aacute;,  Brasil</b></font></p>     <p>&nbsp;</p>     <p>&nbsp;</p>     <p><font size="2" face="Verdana"> <b>Louise  de Souza Canto Ferreira<sup>I</sup>; Jaqueline Helen  Godinho Costa<sup>II</sup>;  Carlos  Ara&uacute;jo da Costa<sup>III</sup>; Marly  de F&aacute;tima Carvalho de Melo<sup>IV</sup>; Marizete Lopes Andrade<sup>V</sup>; Luisa  Car&iacute;cio Martins<sup>III</sup>; Edna  Aoba Yassui Ishikawa<sup>III</sup>; Maisa  Silva de Sousa<sup>III</sup></b></font></p>     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana">  <sup>I</sup><em>Faculdade  de Farm&aacute;cia, Centro Universit&aacute;rio do Par&aacute;, Bel&eacute;m, Par&aacute;, Brasil</em><br />     <sup>II</sup><em>Faculdade  de Ci&ecirc;ncias Biol&oacute;gicas, Instituto de Ci&ecirc;ncias da Sa&uacute;de, Universidade Federal do  Par&aacute;, Bel&eacute;m, Par&aacute;, Brasil</em><br />     <sup>III</sup><em>N&uacute;cleo  de Medicina Tropical, Universidade Federal do Par&aacute;, Bel&eacute;m, Par&aacute;, Brasil</em><br />     <sup>IV</sup><em>Programa  Luz na Amaz&ocirc;nia, Faculdade de Farm&aacute;cia, Instituto de Ci&ecirc;ncias da Sa&uacute;de,  Universidade Federal do Par&aacute;, Bel&eacute;m, Par&aacute;, Brasil</em><br />     <sup>V</sup><em>Programa  Luz na Amaz&ocirc;nia, Sociedade B&iacute;blica do Brasil, Bel&eacute;m, Par&aacute;, Brasil</em></font></p>     <p><font size="2" face="Verdana"><a href="#endereco">Endere&ccedil;o para correspond&ecirc;ncia</a></font><font size="2" face="Verdana"><a href="#endereco"><br /> Correspondence<br /> Direcci&oacute;n para correspondencia</a></font></p>     <p>&nbsp;</p>     <p>&nbsp;</p> <hr size="1" noshade="noshade" />     <p><font size="2" face="Verdana"><strong>RESUMO</strong></font></p>     <p><font size="2" face="Verdana"> O  v&iacute;rus-T linfotr&oacute;pico humano do tipo 1 (HTLV-1) foi o primeiro  retrov&iacute;rus humano a ser identificado e est&aacute; associado a v&aacute;rias doen&ccedil;as  debilitantes. O Estado do Par&aacute; &eacute; o terceiro do Brasil com maior frequ&ecirc;ncia de  infec&ccedil;&atilde;o por HTLV entre doadores de sangue. As comunidades ribeirinhas s&atilde;o  carentes de a&ccedil;&otilde;es de educa&ccedil;&atilde;o e assist&ecirc;ncia &agrave; sa&uacute;de, pela caracter&iacute;stica de  terem moradias espalhadas ao longo de furos e pela dificuldade de acesso aos  centros urbanos. Este estudo objetivou investigar a infec&ccedil;&atilde;o causada pelo HTLV em comunidades  ribeirinhas do nordeste paraense, atendidas pelo Programa Luz na Amaz&ocirc;nia, entre fevereiro de 2009 e junho de 2010. Pesquisa de  anticorpos anti-HTLV-1/2 foi realizada em 175 ribeirinhos, sendo 30 (17,14%) da comunidade de S&atilde;o  Pedro (Acar&aacute;); 62  (35,43%) da comunidade do Furo do Aur&aacute; (Bel&eacute;m) e 83 (47,43%) de Santa Maria  (Acar&aacute;). Nos casos reagentes, m&eacute;todos de biologia molecular foram utilizados  para confirma&ccedil;&atilde;o da infec&ccedil;&atilde;o e identifica&ccedil;&atilde;o do tipo viral. A preval&ecirc;ncia total  do HTLV-1 foi de 1,14%  (2/175), variando entre zero (0/34) em S&atilde;o Pedro, 1,20% (1/83) em Santa Maria e 1,61% (1/62) no Furo do Aur&aacute;. O  HTLV-1 foi identificado em duas das 117 (1,71%) fam&iacute;lias analisadas das tr&ecirc;s  comunidades. N&atilde;o foi observado nenhum caso de transmiss&atilde;o familiar na amostra.  O HTLV-2 n&atilde;o foi encontrado na amostra estudada. Este estudo demonstrou a  ocorr&ecirc;ncia de HTLV-1 nas comunidades ribeirinhas estudadas, com frequ&ecirc;ncias  semelhantes &agrave;s de popula&ccedil;&otilde;es urbanas, indicando a necessidade de maior  investiga&ccedil;&atilde;o e a&ccedil;&otilde;es  de preven&ccedil;&atilde;o das doen&ccedil;as associadas ao v&iacute;rus nessas  comunidades.</font></p>     <p><font size="2" face="Verdana">  <strong>Palavras-chave: </strong>Deltaretrovirus; Estudos  Transversais; Estudos Soroepidemiol&oacute;gicos; ELISA.</font></p> <hr size="1" noshade="noshade" />     <p><font size="2" face="Verdana"><strong>ABSTRACT</strong></font></p>     <p><font size="2" face="Verdana"> The  human T-lymphotropic virus 1 (HTLV-1) was the first human retrovirus  identified, and it is associated with several debilitating diseases. Par&aacute; State  has the third highest frequency rate of HTLC infections among blood donors in Brazil. Its  riparian communities lack educational policies and health care assistance  mainly because they inhabit <em>&quot;furos&quot; </em>(Amazonian river channels)  and do not have easy access to urban centers. This study aimed to investigate  the infection by HTLV in riparian communities of northeastern Par&aacute; included in  the <em>Luz na Amaz&ocirc;nia </em>Program between February 2009 and June 2010. A total of 175 riparian  individuals were selected for detection of anti-HTLV-1/2 antibodies: 30 from  the S&atilde;o Pedro community (Municipality of Acar&aacute;), 62 from the Furo do Aur&aacute; Community  (Municipality of Bel&eacute;m), and 83 from Santa Maria (Municipality of Acar&aacute;). In  the HTLV-reactive individuals we used molecular methods to confirm infection  and identify the viral type. HTLV-2 was not found in the study samples. The  overall prevalence of HTLV-1 was 1.14% (2/1 75), ranging from zero (0/34) in S&atilde;o  Pedro to 1.20% (1/83) in Santa Maria  and 1.61 % (1/62) in Furo do Aur&aacute;. HTLV-1 was identified in two of 117 (1.35%) families  from all three communities. We reported no evidence of familial transmission  through testing of samples. HTLV-2 was not found in the samples tested. This  study demonstrates the occurrence of HTLV-1 in the riparian communities studied, with  frequency rates similar to those of urban populations, which warrants further  research and actions to prevent diseases associated with HTLV in these  communities.</font></p>     <p><font size="2" face="Verdana">  <strong>Keywords: </strong>Deltaretrovirus;  Cross-Sectional Studies; Seroepidemiologic Studies; Enzyme-Linked Immunosorbent  Assay.</font></p> <hr size="1" noshade="noshade" />     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana"><strong>RESUMEN</strong></font></p>     <p><font size="2" face="Verdana"> El virus-T linfotr&oacute;pico humano del tipo 1 (HTLV-1) fue el primer retrovirus  humano  a ser identificado y est&aacute; asociado a varias enfermedades debilitantes. El  Estado de Par&aacute; es el tercero de Brasil  con mayor frecuencia de la infecci&oacute;n por HTLV entre donantes de sangre. Las  comunidades ribere&ntilde;as carecen de acciones de educaci&oacute;n y asistencia a la salud,  por la caracter&iacute;stica de sus viviendas, esparcidas a lo largo de los r&iacute;os y  cursos de agua, y por la dificultad de acceso a los centros urbanos. Este  estudio tuvo como objetivo investigar la infecci&oacute;n causada por el HTLV en  comunidades ribere&ntilde;as del nordeste paraense,  atendidas  por el Programa Luz en la   Amazonia, entre febrero de 2009 y junio de 2010. Fue realizada una  investigaci&oacute;n de anticuerpos anti-HTLV-1/2 en 175 ribere&ntilde;os, siendo 30 (17,14%)  de  la comunidad de S&atilde;o Pedro (Acar&aacute;); 62 (35,43%) de la comunidad del Furo do Aur&aacute; (Bel&eacute;m) y 83 (47,43%)  de  Santa Maria (Acar&aacute;). En los casos  reactivos, se utilizaron m&eacute;todos de biolog&iacute;a molecular para confirmar la  infecci&oacute;n e identificar el tipo viral. La prevalencia total del HTLV-1 fue de 1,14% (2/175), variando entre cero (0/34) en S&atilde;o Pedro, 1,20% (1/83) en Santa Maria  y 1,61% (1/62) en el Furo do Aur&aacute;. El HTLV-1 fue identificado en dos de las  117 (1,71%) familias analizadas de las tres comunidades. No se observ&oacute; ning&uacute;n  caso de transmisi&oacute;n familiar en la muestra. El HTLV-2 no fue hallado en la  muestra estudiada. Este estudio demostr&oacute; la ocurrencia de HTLV-1 en las  comunidades ribere&ntilde;as estudiadas, con frecuencias similares a las de las  poblaciones urbanas, indicando la necesidad de una mayor investigaci&oacute;n y de  acciones de prevenci&oacute;n de las enfermedades asociadas al virus en esas  comunidades.</font></p>     <p><font size="2" face="Verdana">  <strong>Palabras clave: </strong>Deltaretrovirus; Estudios Transversales; Estudios Seroepidemiol&oacute;gicos;  Prueba ELISA.</font></p> <hr size="1" noshade="noshade" />     <p>&nbsp;</p>     <p>&nbsp;</p>     <p><font size="3"><strong><font face="Verdana">INTRODU&Ccedil;&Atilde;O</font></strong></font></p>     <p><font size="2" face="Verdana">Os  v&iacute;rus linfotr&oacute;picos humanos de c&eacute;lulas T (HTLV) pertencem &agrave; fam&iacute;lia <em>Retroviridae, </em>&agrave; subfam&iacute;lia <em>Orthoretrovirinae </em>e ao g&ecirc;nero <em>Deltaretrovirus. </em>Evid&ecirc;ncias  epidemiol&oacute;gicas consistentes apontam o HTLV-1 como agente associado a doen&ccedil;as  como: Leucemia/Linfoma de C&eacute;lulas T do Adulto conhecida como LLTA ou ATL,  Paraparesia Esp&aacute;stica Tropical/Mielopatia Associada ao   HTLV-1  conhecida como PET/MAH ou TSP/HAM, uve&iacute;te e   dermatite  infectiva<sup>1,2,3</sup>. Quanto ao HTLV-2, raramente tem sido associado a  essas doen&ccedil;as<sup>4</sup>. E apenas entre 1% e 4% dos indiv&iacute;duos infectados  ir&atilde;o desenvolver algum tipo de doen&ccedil;a debilitante associada ao v&iacute;rus<sup>5</sup>.</font></p>     <p><font size="2" face="Verdana"> O  HTLV ocorre em todo o mundo, mas sua distribui&ccedil;&atilde;o varia de acordo com a regi&atilde;o  geogr&aacute;fica. O HTLV-1 &eacute; end&ecirc;mico no Jap&atilde;o, Caribe, &Aacute;frica, Am&eacute;rica do Sul e  ilhas da Melan&eacute;sia<sup>6</sup>. No Brasil, estima-se que 2,5 milh&otilde;es de pessoas  estejam infectadas. O v&iacute;rus est&aacute; presente em todos os Estados por&eacute;m com  preval&ecirc;ncias variadas. A Cidade de Salvador apresenta a maior popula&ccedil;&atilde;o de  soropositivos para HTLV entre os doadores de sangue do   Brasil<sup>7,8</sup>.</font></p>     <p><font size="2" face="Verdana"> A  transmiss&atilde;o desse v&iacute;rus pode acontecer de quatro formas: por contato sexual; de m&atilde;e para  filho, atrav&eacute;s da amamenta&ccedil;&atilde;o; por transfus&atilde;o de sangue; e por meio de seringas  e agulhas contendo c&eacute;lulas infectadas com o v&iacute;rus<sup>2,7,8</sup>. O contato celular &eacute; necess&aacute;rio  para que haja a transmiss&atilde;o eficiente entre c&eacute;lulas e indiv&iacute;duos<sup>9</sup>.  Estimativas apontam que, aproximadamente, de 10 a 20 milh&otilde;es de pessoas  estejam infectadas pelo HTLV-1 no mundo. A infec&ccedil;&atilde;o por esse v&iacute;rus tem per&iacute;odo  de lat&ecirc;ncia prolongado, podendo durar algumas d&eacute;cadas ou toda a vida do  indiv&iacute;duo infectado<sup>7</sup>.</font></p>     <p><font size="2" face="Verdana"> A  maioria das comunidades ribeirinhas da Regi&atilde;o Amaz&ocirc;nica tem dificuldade para  obter assist&ecirc;ncia de todo e qualquer tipo, principalmente de a&ccedil;&otilde;es de sa&uacute;de, pela  caracter&iacute;stica de serem as fam&iacute;lias espalhadas em ilhas ou &agrave;s margens de  igarap&eacute;s e furos (pequenos canais), sem acesso f&aacute;cil aos centros urbanos. Este  estudo identificou a frequ&ecirc;ncia e distribui&ccedil;&atilde;o do HTLV-1/2 em comunidades  ribeirinhas, visando minimizar a propaga&ccedil;&atilde;o dessa infec&ccedil;&atilde;o e a ocorr&ecirc;ncia de  doen&ccedil;as associadas.</font></p>     ]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p><font size="3" face="Verdana">  <strong>MATERIAIS  E M&Eacute;TODOS</strong></font></p>     <p><font size="2" face="Verdana"> Entre  fevereiro de 2009  e junho de 2010, o Programa Luz na Amaz&ocirc;nia  atendeu a tr&ecirc;s comunidades ribeirinhas, s&atilde;o elas: S&atilde;o Pedro e Santa Maria, no  Munic&iacute;pio do Acar&aacute; e a comunidade do Furo do Aur&aacute;, do Munic&iacute;pio de Bel&eacute;m. O  referido programa &eacute; uma parceria entre a Sociedade B&iacute;blica do Brasil (SBB) e a  Universidade Federal do Par&aacute; (UFPA) e, com a ajuda de volunt&aacute;rios, desenvolve a&ccedil;&otilde;es de promo&ccedil;&atilde;o &agrave; sa&uacute;de  em comunidades ribeirinhas da regi&atilde;o nordeste do Estado do Par&aacute;.</font></p>     <p><font size="2" face="Verdana"> Uma  investiga&ccedil;&atilde;o sorol&oacute;gica para HTLV foi realizada em fam&iacute;lias cadastradas nas  tr&ecirc;s comunidades ribeirinhas atendidas no per&iacute;odo do estudo, sendo 28 fam&iacute;lias  da comunidade de S&atilde;o Pedro (com 30 indiv&iacute;duos), 46 fam&iacute;lias da comunidade de Santa  Maria (com 83 indiv&iacute;duos)  e 43 fam&iacute;lias do Furo do  Aur&aacute; (com 62 indiv&iacute;duos), correspondendo a um total de 175 indiv&iacute;duos. Foram  inclu&iacute;dos no estudo indiv&iacute;duos de ambos os sexos, maiores de 18 anos de idade,  residentes na comunidade, priorizando  os representantes adultos de cada fam&iacute;lia.</font></p>     <p><font size="2" face="Verdana"> Os  ribeirinhos que se enquadraram nos crit&eacute;rios de inclus&atilde;o foram orientados e  convidados a participar do estudo, assinando o Termo de Consentimento Livre e  Esclarecido. O projeto de pesquisa foi analisado e aprovado por Comit&ecirc; de &Eacute;tica em Pesquisa em Seres Humanos,  segundo o protocolo de n<sup>o</sup> 071/2006-CEP/NMT.</font></p>     <p><font size="2" face="Verdana"> Palestras  sobre os objetivos da investiga&ccedil;&atilde;o foram realizadas em todas as comunidades e  as amostras de sangue foram obtidas ap&oacute;s o consentimento de cada indiv&iacute;duo. O  question&aacute;rio epidemiol&oacute;gico foi preenchido no momento da coleta da amostra  sangu&iacute;nea, identificando vari&aacute;veis como a idade, o g&ecirc;nero, hist&oacute;rico de  transfus&otilde;es sangu&iacute;neas ou de hemoderivados e uso de drogas injet&aacute;veis, dentre  outros. Todas as amostras de sangue coletadas foram testadas pelo m&eacute;todo de  ensaio imunoenzim&aacute;tico (ELISA), para a detec&ccedil;&atilde;o de anticorpos anti-HTLV-1/2  (Ortho<sup>&reg;</sup>, USA), de acordo com instru&ccedil;&otilde;es do fabricante. As amostras com  resultados reagentes e com valores pr&oacute;ximos aos do <em>cutoff, </em>foram  testadas em duplicata.</font></p>     <p><font size="2" face="Verdana"> As  amostras consideradas positivas pelo ELISA foram analisadas pela t&eacute;cnica de  rea&ccedil;&atilde;o em cadeia da polimerase (PCR), seguida de digest&atilde;o enzim&aacute;tica para  confirma&ccedil;&atilde;o da infec&ccedil;&atilde;o e diferencia&ccedil;&atilde;o dos tipos 1 e 2 de HTLV. A t&eacute;cnica  emprega a detec&ccedil;&atilde;o do DNA proviral pela amplifica&ccedil;&atilde;o da regi&atilde;o <em>Px </em>do  v&iacute;rus. Para a rea&ccedil;&atilde;o  de PCR foi utilizada solu&ccedil;&atilde;o com 5,0 &#181;L de Go Taq<sup>&reg;</sup> Green  Master Mix,  2,0 &#181;L de &aacute;gua, 1 &#181;L (10 pmol) de cada <em>primer </em>HTLV_Externo  F 5'-TTCCCAGGGTTTGGACGAAG-3' (7219-7238, direto) e HTLV_Externo R 5'-GGGTAAG GACCTTGAGGGTC-3' (7483-7464, reverso) e 1,0 &#181;L de DNA, para um  volume final de 10 &#181;L.  O protocolo para amplifica&ccedil;&atilde;o seguiu a temperatura de desnatura&ccedil;&atilde;o de 94<sup>o</sup>  C por 4 min,  seguida de 30 ciclos  (repeti&ccedil;&otilde;es), onde a temperatura de desnatura&ccedil;&atilde;o foi de 94<sup>o </sup>C por 40  seg, a temperatura de anelamento a 51,6<sup>o</sup> C por 30 seg e, por fim, a  temperatura de extens&atilde;o a 72<sup>o</sup> C por 40 seg, seguida da temperatura  de extens&atilde;o final de 72<sup>o</sup> C, 10 min, e 10<sup>o</sup> C por 10 min<sup>10</sup>.</font></p>     <p><font size="2" face="Verdana"> A  identifica&ccedil;&atilde;o molecular do genoma viral foi realizada por uma <i>nested</i>-PCR, utilizando-se as mesmas quantidades  de reagentes da primeira PCR e 1 &#181;L (10 pmol) de cada <em>primer </em>HTLV_interno  F 5'CGGATACCCAGT CTACGTGTT3' (7248-7268, direto) e HTLV_interno R   5'GAGCCGATAACGCGTCCATCG3'  (7406-7386,   reverso).  O protocolo de amplifica&ccedil;&atilde;o seguiu-se em 35 ciclos (repeti&ccedil;&otilde;es), com  temperatura de desnatura&ccedil;&atilde;o de 94<sup>o</sup> C por 30 seg, a temperatura de  anelamento de 51,6<sup>o</sup> C por 30 seg e a temperatura de extens&atilde;o de 72<sup>o</sup>  C por 30 seg, seguido da temperatura de extens&atilde;o final a 72<sup>o</sup> C, 10  min, e 10<sup>o</sup> C por 10 min<sup>10</sup>.</font></p>     <p><font size="2" face="Verdana"> Todas  as amostras de DNA foram previamente amplificadas para um fragmento do gene da  globina humana, utilizando as mesmas condi&ccedil;&otilde;es de reagentes, com exce&ccedil;&atilde;o dos  oligonuclet&iacute;deos espec&iacute;ficos para HPV, que foram substitu&iacute;dos pelos oligonuclet&iacute;deos  G73 e G74<sup>11</sup>. Foram utilizados controles positivo (amostra  sabidamente positiva) e negativo (&aacute;gua est&eacute;ril) a cada rea&ccedil;&atilde;o de PCR.</font></p>     <p><font size="2" face="Verdana"> Ap&oacute;s  a identifica&ccedil;&atilde;o dos casos com resultados de PCR positivos, foi realizada a  digest&atilde;o enzim&aacute;tica destes, para identificar o tipo de HTLV presente na  amostra. A rea&ccedil;&atilde;o enzim&aacute;tica utilizou a enzima <em>Taq </em>I (Promega<sup>&reg;</sup>) seguindo  as recomenda&ccedil;&otilde;es do fabricante. A cada rea&ccedil;&atilde;o enzim&aacute;tica foi utilizado um  controle positivo para HTLV-2. Os produtos de PCR e de digest&atilde;o enzim&aacute;tica foram  visualizados em gel de agarose a 2% e a 3%, respectivamente,  contendo brometo de et&iacute;dio (1 mg/mL), sob luz UV.</font></p>     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana"> Os  comunicantes e familiares dos indiv&iacute;duos confirmados com a infec&ccedil;&atilde;o viral foram  investigados quanto &agrave; transmiss&atilde;o familiar do HTLV-1/2, obedecendo aos  crit&eacute;rios de investiga&ccedil;&atilde;o do c&ocirc;njuge, m&atilde;e e filhos, quando a pessoa infectada  fosse do sexo feminino; e c&ocirc;njuge e m&atilde;e, quando fosse do sexo masculino.</font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana">  <strong>RESULTADOS</strong></font></p>     <p><font size="2" face="Verdana"> A  investiga&ccedil;&atilde;o sorol&oacute;gica para HTLV-1/2 foi realizada em 117 das 149 (78,52%) fam&iacute;lias cadastradas  no Programa Luz na Amaz&ocirc;nia,  no per&iacute;odo de janeiro de 2009   a junho de 2010, sendo 28 fam&iacute;lias da  comunidade de S&atilde;o Pedro (30 indiv&iacute;duos),  46 fam&iacute;lias de Santa  Maria (83 indiv&iacute;duos)  e 43 do Furo do Aur&aacute; (62 indiv&iacute;duos),  correspondendo a um total de 175 indiv&iacute;duos.</font></p>     <p><font size="2" face="Verdana"> A  <a href="#t1">tabela 1</a>  por g&ecirc;nero,   demonstra a distribui&ccedil;&atilde;o,  por faixa et&aacute;ria e da demanda de 175 ribeirinhos que participaram do estudo: idade variando de 18 a 85  anos e  m&eacute;dia de 41 anos; 93,14% (163/175) das pessoas com idade igual ou superior a 20 anos. Identificou-se tamb&eacute;m uma maior frequ&ecirc;ncia, 58,28% (102/175), de  indiv&iacute;duos do sexo feminino na amostra analisada das tr&ecirc;s comunidades.</font></p>     <p><a name="t1" id="t1"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/rpas/v1n3/3a14t1.gif" border="0"></p>     <p>&nbsp;</p>     <p><font size="2" face="Verdana"> A  presen&ccedil;a de anticorpos anti-HTLV-1/2 foi identificada em duas das 175 amostras analisadas,  caracterizando uma preval&ecirc;ncia de 1,14%. A frequ&ecirc;ncia de anticorpos variou de  zero (0/30) na comunidade de S&atilde;o Pedro a   1,20%  (1/83) na comunidade de Santa Maria e 1,61%   (1/62)  na comunidade do Furo do Aur&aacute;. As frequ&ecirc;ncias de HTLV-1/2 n&atilde;o divergiram  estatisticamente entre as tr&ecirc;s comunidades estudadas (p = 0,7525). Os dois indiv&iacute;duos  soropositivos tinham idade de 20 e 65 anos, sendo do sexo feminino e masculino,  respectivamente.</font></p>     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana"> Resultados da PCR confirmaram a amplifica&ccedil;&atilde;o do  fragmento do genoma proviral do HTLV-1/2 nas duas amostras ELISA positivas e o  tipo HTLV-1 foi identificado pela digest&atilde;o enzim&aacute;tica em ambas as amostras, n&atilde;o  tendo sido encontrado nenhum caso de HTLV-2.</font></p>     <p><font size="2" face="Verdana"> A  pesquisa de anticorpos anti-HTLV-1/2 nos familiares da mulher ribeirinha com  infec&ccedil;&atilde;o confirmada por HTLV-1 foi negativa. Desta fam&iacute;lia foram analisados  seus dois filhos (com idades de dois e quatro anos), sua m&atilde;e e seu c&ocirc;njuge. O  outro caso, tamb&eacute;m positivo para HTLV-1, relatou ser vi&uacute;vo, n&atilde;o ter pais vivos,  n&atilde;o ter filhos e nem outro familiar residindo na mesma comunidade,  impossibilitando a an&aacute;lise de seus comunicantes. Nenhum dos indiv&iacute;duos  infectados por HTLV-1 relatou hist&oacute;ria de transfus&atilde;o sangu&iacute;nea ou uso de drogas  endovenosas.</font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana">  <strong>DISCUSS&Atilde;O</strong></font></p>     <p><font size="2" face="Verdana"> A  infec&ccedil;&atilde;o pelo HTLV-1/2 se caracteriza pelo seu agrupamento em &aacute;reas geogr&aacute;ficas  definidas no mundo; pela varia&ccedil;&atilde;o espacial das taxas de soropreval&ecirc;ncia, dentro  de &aacute;reas de preval&ecirc;ncia reconhecidamente elevadas; pelo aumento da  soropreval&ecirc;ncia com a idade (efeito da idade, efeito de coorte, soroconvers&atilde;o  tardia); e soropreval&ecirc;ncia mais elevada em mulheres, tornando-se mais acentuada  ap&oacute;s os 40 anos  de idade<sup>10</sup>.</font></p>     <p><font size="2" face="Verdana"> No  Brasil, at&eacute; o momento, n&atilde;o existem estudos epidemiol&oacute;gicos com bases  populacionais e com metodologias adequadas sobre a infec&ccedil;&atilde;o pelo HTLV que  permitam conhecer sua real preval&ecirc;ncia<sup>6</sup>. A principal maneira de  aferi&ccedil;&atilde;o da preval&ecirc;ncia da infec&ccedil;&atilde;o tem sido realizada pela an&aacute;lise sorol&oacute;gica  de doadores em bancos de sangue, onde as taxas encontradas nas capitais  brasileiras variam de 0,04% em Florian&oacute;polis, Santa Catarina, a 1,80% em  Salvador, Bahia<sup>7,8,12</sup>. A soropreval&ecirc;ncia de HTLV-1/2 deste estudo,  de 1,14%, encontra-se inserida na varia&ccedil;&atilde;o encontrada entre os doadores de  sangue no Brasil e na varia&ccedil;&atilde;o de 0,91% a 1,61% encontrada nos doadores de  sangue do Estado do Par&aacute;<sup>7,8</sup>.</font></p>     <p><font size="2" face="Verdana"> Como  os ensaios imunoenzim&aacute;ticos est&atilde;o sujeitos a frequentes rea&ccedil;&otilde;es falsopositivas<sup>13,14,15</sup>,  o imunodiagn&oacute;stico do retrov&iacute;rus depende de confirma&ccedil;&atilde;o da sororreatividade por  meio de  <em>Western Blot </em>(WB) ou da PCR. Neste sentido, outros estudos  demonstram preval&ecirc;ncia de infec&ccedil;&atilde;o pelo HTLV confirmada pela t&eacute;cnica do WB de 0,3% no interior da Bahia<sup>16</sup>,  0,11% em Rio Branco, Acre<sup>17</sup>,  0,07% em  Maring&aacute;, Paran&aacute;<sup>18</sup> e 0,02% em Uberaba, Minas Gerais<sup>19</sup>. Neste estudo, a  infec&ccedil;&atilde;o por HTLV-1 foi confirmada por m&eacute;todos moleculares em todas as amostras  sorologicamente reagentes para HTLV-1/2.</font></p>     <p><font size="2" face="Verdana"> A alta preval&ecirc;ncia da infec&ccedil;&atilde;o por HTLV na Regi&atilde;o  Amaz&ocirc;nica, especialmente no Estado do Par&aacute;, que se destaca como o terceiro em  n&uacute;mero de casos entre doadores de sangue do Brasil<sup>7,8</sup>, tem suscitado  estudos soroepidemiol&oacute;gicos e moleculares direcionados para comunidades com  popula&ccedil;&otilde;es espec&iacute;ficas, j&aacute; tendo sido registrada preval&ecirc;ncia de 1,8% para  HTLV-1, entre imigrantes japoneses<sup>20</sup>, e a varia&ccedil;&atilde;o de zero a 2,06%  para HTLV-1 e de zero a 1,06% para HTLV-2 em comunidades remanescentes de  quilombolas, na Ilha do Maraj&oacute; (Par&aacute;, Brasil)<sup>21</sup>. O HTLV-2 tamb&eacute;m foi  identificado em at&eacute; 30% de  comunidades ind&iacute;genas amaz&ocirc;nicas<sup>22</sup> e em 29% das amostras  sororreagentes de doadores paraenses, mas nas comunidades ribeirinhas objeto  deste estudo s&oacute; o HTLV-1 foi encontrado.</font></p>     <p><font size="2" face="Verdana"> A varia&ccedil;&atilde;o na preval&ecirc;ncia de HTLV de comunidades estudadas  previamente, assim como neste estudo, demonstrou que o v&iacute;rus ainda n&atilde;o penetrou  em certas comunidades, onde provavelmente os fatores associados &agrave; exposi&ccedil;&atilde;o s&atilde;o  menos frequentes.  Por outro lado, considerando que s&atilde;o popula&ccedil;&otilde;es  pequenas, a presen&ccedil;a de uma &uacute;nica pessoa pode elevar esta preval&ecirc;ncia a &iacute;ndices  pr&oacute;ximos ou acima dos encontrados na popula&ccedil;&atilde;o em geral. Al&eacute;m disso, a  partir do momento em que se encontra um caso positivo em uma comunidade fechada  existe uma chance maior desse v&iacute;rus se propagar de forma silenciosa,  contribuindo para um aumento da infec&ccedil;&atilde;o e das doen&ccedil;as associadas.</font></p>     <p><font size="2" face="Verdana"> A partir da no&ccedil;&atilde;o adquirida,  em pesquisa anterior<sup>23</sup>, sobre a forma silenciosa com que o HTLV se  propaga no seio das fam&iacute;lias, o presente trabalho objetivou tamb&eacute;m investigar a  transmiss&atilde;o familiar da infec&ccedil;&atilde;o entre os ribeirinhos, por&eacute;m nenhum caso foi  identificado na fam&iacute;lia investigada. Estudos epidemiol&oacute;gicos relatam um aumento da infec&ccedil;&atilde;o com a  idade, que pode ocorrer por soroconvers&atilde;o tardia de infec&ccedil;&atilde;o adquirida no  in&iacute;cio da vida ou pelo risco cumulativo de novas infec&ccedil;&otilde;es ao  longo da vida<sup>24</sup>. Neste sentido, seria importante investigar os  filhos do caso portador <em>a posteriori, </em>visto  que ainda s&atilde;o crian&ccedil;as e que houve relato de amamenta&ccedil;&atilde;o natural por um longo  per&iacute;odo.</font></p>     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana"> A amostra de fam&iacute;lias analisadas neste estudo &eacute; significativa para  inferir dados estat&iacute;sticos sobre as tr&ecirc;s comunidades estudadas e pode at&eacute;  representar a realidade das comunidades ribeirinhas localizadas pr&oacute;ximas &agrave;  Cidade de Bel&eacute;m, mas n&atilde;o deve demonstrar a preval&ecirc;ncia da infec&ccedil;&atilde;o pelo  HTLV-1/2 na popula&ccedil;&atilde;o de ribeirinhos do Estado do Par&aacute;, devido &agrave; grande  diversidade dessa popula&ccedil;&atilde;o, o que pode estar relacionado ou n&atilde;o aos fatores  associados &agrave; infec&ccedil;&atilde;o.</font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana">  <strong>CONCLUS&Atilde;O</strong></font></p>     <p><font size="2" face="Verdana"> A preval&ecirc;ncia do HTLV-1 na amostra de comunidades ribeirinhas  investigadas foi de 1,14%, variando de zero a 1,61%, n&atilde;o tendo sido encontrado  nenhum caso de HTLV-2 e tamb&eacute;m nenhum caso de transmiss&atilde;o familiar. Uma melhor  vis&atilde;o sobre a preval&ecirc;ncia da infec&ccedil;&atilde;o por HTLV-1/2 na popula&ccedil;&atilde;o ribeirinha do  Estado do Par&aacute; seria obtida por um estudo epidemiol&oacute;gico de base populacional.  Esse conhecimento &eacute; importante na preven&ccedil;&atilde;o de novas infec&ccedil;&otilde;es e de doen&ccedil;as  associadas a esses v&iacute;rus.</font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana">  <strong>APOIO FINANCEIRO</strong></font></p>     <p><font size="2" face="Verdana"> Este trabalho obteve suporte  financeiro da Funda&ccedil;&atilde;o de Amparo &agrave; Pesquisa do Estado do Par&aacute; (PPSUS-PA  2006-2007_PROJ_428_9577372), em colabora&ccedil;&atilde;o com a UFPA e a SBB.</font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><strong>REFER&Ecirc;NCIAS</strong></font></p>     <!-- ref --><p><font size="2" face="Verdana">  1 Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL. Global epidemiology of  HTLV-I infection and associated diseases. Oncogene. 2005 Sep;24(39):6058-68. DOI:10.1038/SJ.ONC.1208968</font><font size="2" face="verdana"><font size="2" face="verdana">&nbsp; &nbsp; &nbsp; &nbsp;  &nbsp;&#91; <a href="http://www.nature.com/onc/journal/v24/n39/full/1208968a.html" target="_blank">Links</a> &#93;</font></font><!-- ref --><p><font size="2" face="Verdana"> 2 Bittencourt AL. Vertical  transmission of HTLV-I/II: a review. Rev Inst Med Trop Sao Paulo. 1998 Jul-</font><font size="2" face="Verdana">Aug;40(4):245-51. DOI:10.1590/S0036-46651998000400008 </font><font size="2" face="verdana"><font size="2" face="verdana">&nbsp; &nbsp; &nbsp; &nbsp;  &nbsp;&#91; <a href="http://www.scielo.br/scielo.php?script=sci_arttext&amp;pid=S0036-46651998000400008&amp;lng=en&amp;nrm=iso" target="_blank">Links</a> &#93;</font></font><!-- ref --><p><font size="2" face="Verdana"> 3 Spalton DJ, Nicholson F.  HTLV-I infection in human disease. Br  J Ophthalmol. 1991 Mar;75(3):174-5.</font><font size="2" face="verdana"><font size="2" face="verdana">&nbsp; &nbsp; &nbsp; &nbsp;  &nbsp;&#91; <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1042300/pdf/brjopthal00565-0047.pdf" target="_blank">Links</a> &#93;</font></font><!-- ref --><p><font size="2" face="Verdana"> 4 Posada-Vergara MP, Montanheiro P,  Fukumori LM, Bonasser F, Duarte AJ, Penalva de Oliveira AC, et al. Clinical and  epidemiological aspects of HTLV-II infection in S&atilde;o Paulo, Brazil: presence of  tropical spastic paraparesis/HTLV-associated myelopathy (TSP/HAM) simile  diagnosis in HIV-1-co-infected subjects. Rev  Inst Med Trop Sao Paulo. 2006 Jul-Aug;48(4):207-10.</font><font size="2" face="verdana"><font size="2" face="verdana"> DOI:10.1590/S0036-46652006000400006&nbsp; &nbsp; &nbsp; &nbsp;  &nbsp;&#91; <a href="http://www.scielo.br/scielo.php?script=sci_arttext&amp;pid=S0036-46652006000400006&amp;lng=en&amp;nrm=iso&amp;tlng=en" target="_blank">Links</a> &#93;</font></font><!-- ref --><p><font size="2" face="Verdana">5 Santos FLN, Lima FWM. Epidemiologia, fisiopatogenia  e diagn&oacute;stico  laboratorial da infec&ccedil;&atilde;o pelo HTLV-I. J Bras Patol Med Lab. 2005 abr;41(2):105-16. DOI:10.1590/S1676-24442005000200008</font><font size="2" face="verdana"><font size="2" face="verdana">&nbsp; &nbsp; &nbsp; &nbsp;  &nbsp;&#91; <a href="http://www.scielo.br/scielo.php?script=sci_arttext&amp;pid=S1676-24442005000200008" target="_blank">Links</a> &#93;</font></font><!-- ref --><p><font size="2" face="Verdana"> 6 Gon&ccedil;alves DU, Proietti FA, Ribas JG, Ara&uacute;jo MG, Pinheiro SR,  Guedes AC, et al. Epidemiology, treatment, and prevention of human T-cell leukemia virus  type 1-associated diseases. Clin Microbiol Rev.   2010  Jul;23(3):577-89.</font><font size="2" face="verdana"><font size="2" face="verdana">&nbsp; &nbsp; &nbsp; &nbsp;  &nbsp;&#91; <a href="http://www.ncbi.nlm.nih.gov/pubmed/20610824" target="_blank">Links</a> &#93;</font></font><!-- ref --><p><font size="2" face="Verdana"> 7 Carneiro-Proietti ABF, Ribas JGR, Catalan-Soares BC, Martins ML, Brito-Melo GEA, Mertins-Filho  AO, et al. Infec&ccedil;&atilde;o e doen&ccedil;a pelos v&iacute;rus linfotr&oacute;picos  humanos de c&eacute;lulas T (HTLV-I/II) no Brasil. Rev Soc Bras  Med   Trop. 2002 set-out;35(5):499-508.</font><font size="2" face="verdana"><font size="2" face="verdana">&nbsp; &nbsp; &nbsp; &nbsp;  &nbsp;&#91; <a href="http://biblioteca.universia.net/html_bura/ficha/params/id/304384.html" target="_blank">Links</a> &#93;</font></font><!-- ref --><p><font size="2" face="Verdana">8 Catalan-Soares B, Carneiro-Proietti AB,  Proietti FA. Interdisciplinary HTLV Research Group. Heterogeneous geographic  distribution of human T-cell lymphotropic viruses I and II (HTLV-I/II): serological  screening prevalence rates in blood donors from large urban areas in Brazil. Cad  Saude Publica. 2005 May-Jun;21(3):926-31. DOI:10.1590/S0102-311X2005000300027</font><font size="2" face="verdana"><font size="2" face="verdana">&nbsp; &nbsp; &nbsp; &nbsp;  &nbsp;&#91; <a href="http://www.scielosp.org/scielo.php?script=sci_arttext&amp;pid=S0102-311X2005000300027&amp;lng=en&amp;nrm=iso&amp;tlng=en" target="_blank">Links</a> &#93;</font></font><!-- ref --><p><font size="2" face="Verdana"> 9 Igakura T, Stinchcombe JC,  Goon PKC, Taylor GP, Weber JN, Griffiths GM, et al. Spread of HTLV-I between  lymphocytes by virus-induced polarization of the cytoskeleton. Science. 2003  Mar;299(5613):1713-6.</font><font size="2" face="verdana"><font size="2" face="verdana">&nbsp; &nbsp; &nbsp; &nbsp;  &nbsp;&#91; <a href="http://www.ncbi.nlm.nih.gov/pubmed/12589003" target="_blank">Links</a> &#93;</font></font><!-- ref --><p><font size="2" face="Verdana"> 10 Tuke PW, Luton  P, Garson JA. Differential diagnosis of HTLV-I and HTLV-II infections by  restriction enzyme analysis of nested PCR productes. J Virol Methods. 1992  Nov;40(2):163-74. DOI:  10.1016/0166-0934(92)90065-L</font><font size="2" face="verdana"><font size="2" face="verdana">&nbsp; &nbsp; &nbsp; &nbsp;  &nbsp;&#91; <a href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6T96-476RMPB-50&amp;_user=10&amp;_coverDate=11%2F30%2F1992&amp;_rdoc=1&amp;_fmt=high&amp;_orig=search&amp;_origin=search&amp;_sort=d&amp;_docanchor=&amp;view=c&amp;_acct=C000050221&amp;_version=1&amp;_urlVersion=0&amp;_userid=10&amp;md5=467e6e49a7989072e" target="_blank">Links</a> &#93;</font></font><!-- ref --><p><font size="2" face="Verdana"> 11 Greer CE, Peterson SL, Kiviat NB,  Manos MM. PCR amplification from paraffin-embedded tissues: effects of fixative  and fixation time. Am  J Clin Pathol. 1991   Feb;95(2):117-24.</font><font size="2" face="verdana"><font size="2" face="verdana">&nbsp; &nbsp; &nbsp; &nbsp;  &nbsp;&#91; <a href="http://www.ncbi.nlm.nih.gov/pubmed/1846996" target="_blank">Links</a> &#93;</font></font><!-- ref --><p><font size="2" face="Verdana"> 12 Salles NA, Sabino EC, Barreto CB, Barreto AME, Otani  MM, Chamone DF. Descarte de bolsas de sangue e preval&ecirc;ncia de doen&ccedil;as  infecciosas em doadores de sangue da Funda&ccedil;&atilde;o Pr&oacute;-Sangue/Hemocentro de S&atilde;o  Paulo. Rev  Panam Salud Publica. 2003 Feb-Mar;13(2-3):111-6. DOI:10.1590/S1020-49892003000200011</font><font size="2" face="verdana"><font size="2" face="verdana">&nbsp; &nbsp; &nbsp; &nbsp;  &nbsp;&#91; <a href="http://www.scielosp.org/scielo.php?pid=S1020-49892003000200011&amp;script=sci_arttext" target="_blank">Links</a> &#93;</font></font><!-- ref --><p><font size="2" face="Verdana"> 13 Zehender G,  Maddalena C, Gianotto M, Cavalli B, Santambrogio S, Orso M, et al. High  prevalence of false-negative anti-HTLV type I/II enzyme-linked immunosorbent  assay results in HIV type 1-positive patients. AIDS Res Hum Retroviruses. 1997   Sep;13(13):1141-6.</font><font size="2" face="verdana"><font size="2" face="verdana">&nbsp; &nbsp; &nbsp; &nbsp;  &nbsp;&#91; <a href="High%20prevalence%20of%20false-negative%20anti-HTLV%20type%20I/II%20enzyme-linked%20immunosorbent%20assay%20results%20in%20HIV%20type%201-positive%20patients." target="_blank">Links</a> &#93;</font></font><!-- ref --><p><font size="2" face="Verdana"> 14 Caterino-de-Araujo  A, Chieco-Bianchi L, Meleiro MC, Suleiman J, Calabro ML,  Favero A, et al. Sensitivity of two enzyme-linked immunosorbent  assay tests in relation to western blot in detecting human T-cell lymphotropic  virus types I and II infection among HIV-1 infected patients from S&atilde;o Paulo,  Brazil. Diagn  Microbiol Infect Dis. 1998 Mar;30(3):173-82. </font><font size="2" face="verdana"><font size="2" face="verdana">DOI:10.1016/S0732-8893(97)00236-8&nbsp;&nbsp; &nbsp; &nbsp; &nbsp;  &nbsp;&#91; <a href="http://www.ncbi.nlm.nih.gov/pubmed/9572023" target="_blank">Links</a> &#93;</font></font><!-- ref --><p><font size="2" face="Verdana"> 15 Poiesz BJ, Dube S, Choi D, Esteban E, Ferrer J, Leon&shy;Ponte M,  et al. Comparative  performances of an HTLV-I/II EIA and other serologic and PCR assays on samples  from persons at risk for HTLV-II infection. Transfusion.   2000 Aug;40(8):924-30. DOI:10.1046/j.1537-2995.2000.40080924.x</font><font size="2" face="verdana"><font size="2" face="verdana">&nbsp; &nbsp; &nbsp; &nbsp;  &nbsp;&#91; <a href="http://onlinelibrary.wiley.com/doi/10.1046/j.1537-2995.2000.40080924.x/abstract" target="_blank">Links</a> &#93;</font></font><!-- ref --><p><font size="2" face="Verdana"> 16 Britto APCR, Galv&atilde;o-Castro B, Straatmann A, Santos-Torres S,  Tavares-Neto J. Infec&ccedil;&atilde;o pelo HTLV-I/II no Estado da Bahia. Rev  Soc Bras Med Trop. 1998 jan-fev;31(1):35-41.</font><font size="2" face="verdana"><font size="2" face="verdana"> DOI:  10.1590/S0037-86821998000100005&nbsp; &nbsp; &nbsp; &nbsp;  &nbsp;&#91; <a href="http://www.scielo.br/scielo.php?script=sci_arttext&amp;pid=S0037-86821998000100005&amp;lng=pt&amp;nrm=iso&amp;tlng=pt" target="_blank">Links</a> &#93;</font></font><!-- ref --><p><font size="2" face="Verdana"> 17 Colin DD, Alc&acirc;ntara J&uacute;nior LC,  Santos FL, Uch&ocirc;a R, Tavares-Neto J. Seroprevalence of human T cell lymphotropic  virus infection and associated factors of risk in blood donors of Rio Branco  city, AC, Brazil   (1998-2001).  Rev Soc Bras Med Trop. 2003 Nov-Dec;36(6):677-83.</font><font size="2" face="verdana"><font size="2" face="verdana">&nbsp; &nbsp; &nbsp; &nbsp;  &nbsp;&#91; <a href="http://www.ncbi.nlm.nih.gov/pubmed/15049106" target="_blank">Links</a> &#93;</font></font><!-- ref --><p><font size="2" face="Verdana"> 18 Veit APT, Mella EAC,  Mella-Junior SE. Soropreval&ecirc;ncia do v&iacute;rus linfotr&oacute;pico  de c&eacute;lulas T humanas (HTLV-I/II) em  indiv&iacute;duos doadores de sangue do hemocentro da cidade de Maring&aacute;-PR. Arq Cienc  Saude Unipar Umuarama. 2006  set-dez;10(3):123-6.</font><font size="2" face="verdana"><font size="2" face="verdana">&nbsp; &nbsp; &nbsp; &nbsp;  &nbsp;&#91; <a href="http://bases.bireme.br/cgi-bin/wxislind.exe/iah/online/?IsisScript=iah/iah.xis&amp;src=google&amp;base=LILACS&amp;lang=p&amp;nextAction=lnk&amp;exprSearch=498947&amp;indexSearch=ID" target="_blank">Links</a> &#93;</font></font><!-- ref --><p><font size="2" face="Verdana"> 19 Lima GM, Eust&aacute;quio JMJ, Martins RA, Josahkian JA,  Pereira GA, Moraes-Souza H, et al. Decline in the  prevalence of HTLV-1/2 among blood donors at the Regional  Blood Center  of the City of Uberaba,  State of   Minas  Gerais, from 1995 to 2008. Rev Soc Bras Med Trop. 2010 Jul-Aug;43(4):421-4. DOI:10.1590/S0037-86822010000400017</font><font size="2" face="verdana"><font size="2" face="verdana">&nbsp; &nbsp; &nbsp; &nbsp;  &nbsp;&#91; <a href="http://www.scielo.br/scielo.php?script=sci_arttext&amp;pid=S0037-86822010000400017&amp;lng=en&amp;nrm=iso&amp;tlng=en" target="_blank">Links</a> &#93;</font></font><!-- ref --><p><font size="2" face="Verdana"> 20 Vallinoto AC, Muto NA, Pontes GS, Machado LF, Azevedo VN, Santos  SE, et al. Serological  and molecular evidence of HTLV-I infection among Japanese immigrants living in  the Amazon region of Brazil. Jpn J  Infect Dis. 2004 Aug;57(4):156-9.</font><font size="2" face="verdana"><font size="2" face="verdana">&nbsp; &nbsp; &nbsp; &nbsp;  &nbsp;&#91; <a href="http://www.ncbi.nlm.nih.gov/pubmed/15329447" target="_blank">Links</a> &#93;</font></font><!-- ref --><p><font size="2" face="Verdana"> 21 Vallinoto AC, Pontes GS, Muto NA, Lopes IG, Machado LF, Azevedo  VN, et al. Identification  of human T-cell lymphotropic virus infection in a semi-isolated Afro-Brazilian quilombo  located in the Maraj&oacute; Island (Par&aacute;, Brazil). Mem Inst Oswaldo Cruz. 2006 Feb;101(1):103-5. DOI:10.1590/S0074-02762006000100020</font><font size="2" face="verdana"><font size="2" face="verdana">&nbsp; &nbsp; &nbsp; &nbsp;  &nbsp;&#91; <a href="http://www.scielo.br/scielo.php?script=sci_arttext&amp;pid=S0074-02762006000100020" target="_blank">Links</a> &#93;</font></font><!-- ref --><p><font size="2" face="Verdana"> 22 Ishak R, Harrington Jr WJ, Azevedo VN, Eiraku N, Ishak MO,  Guerreiro JF, et al. Identification of human T cell lymphotropic virus type IIa infection in  the Kayapo, an indigenous population of Brazil. AIDS Res Hum Retroviruses. 1995 Jul;11(7):813-21.</font><font size="2" face="verdana"><font size="2" face="verdana">&nbsp; &nbsp; &nbsp; &nbsp;  &nbsp;&#91; <a href="http://www.ncbi.nlm.nih.gov/pubmed/7546908" target="_blank">Links</a> &#93;</font></font><!-- ref --><p><font size="2" face="Verdana"> 23 Catalan-Soares B, Carneiro-Proietti AB, Proietti  FA. Grupo Interdisciplinar de Pesquisas em HTLV. Human T-cell lymphotropic virus in family  members of seropositive blood donors: silent dissemination. Rev Panam Salud Publica.  2004 Dec;16(6):387-94.</font><font size="2" face="verdana"><font size="2" face="verdana">&nbsp; &nbsp; &nbsp; &nbsp;  &nbsp;&#91; <a href="http://www.scielosp.org/scielo.php?script=sci_arttext&amp;pid=S1020-49892004001200004" target="_blank">Links</a> &#93;</font></font><!-- ref --><p><font size="2" face="Verdana"> 24 Murphy EL, Wilks R, Morgan  OS, Hanchard B,   Cranston B, Figueroa JP, et al. Health effects of  human T-lymphotropic virus type I (HTLV-I) in a Jamaican cohort. Int J  Epidemiol. 1996;25(5):1090-7.</font><font size="2" face="verdana"><font size="2" face="verdana">&nbsp; &nbsp; &nbsp; &nbsp;  &nbsp;&#91; <a href="http://www.ncbi.nlm.nih.gov/pubmed/8921499" target="_blank">Links</a> &#93;</font></font><p>&nbsp;</p>     <p>&nbsp;</p>     <p><font size="2" face="Verdana"><b><a name="endereco" id="endereco"></a><a href="#topo"><img src="/img/revistas/rpas/v1n3/seta.gif" border="0" /></a></b><strong>Correspond&ecirc;ncia / Correspondence  / Correspondencia:</strong><br />   Ma&iacute;sa  Silva de Sousa<br />   N&uacute;cleo de Medicina Tropical,<br />   Universidade Federal do  Par&aacute;<br />   Av. General&iacute;ssimo Deodoro, 92.<br />   Bairro: Umarizal<br />   CEP: 66055-240<br />   Bel&eacute;m-Par&aacute;-Brasil<br />   Tel./Fax: (91)  3241-4681<br />   E-mail:<a href="mailto:maisasousa@ufpa.br">maisasousa@ufpa.br</a></font></p>     <p><font size="2" face="Verdana">Recebido em / Received / Recibido  en: 1/9/2010<br /> Aceito em / Accepted / Aceito en: 25/9/2010</font></p> <script type="text/javascript"> var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www."); document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E")); </script> <script type="text/javascript"> try { var pageTracker = _gat._getTracker("UA-7885746-4"); pageTracker._setDomainName("none"); pageTracker._setAllowLinker(true); pageTracker._trackPageview(); } catch(err) {}</script>      ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Proietti]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[Carneiro-Proietti]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Catalan-Soares]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Global epidemiology of HTLV-I infection and associated diseases]]></article-title>
<source><![CDATA[Oncogene]]></source>
<year>2005</year>
<month> S</month>
<day>ep</day>
<volume>24</volume>
<numero>39</numero>
<issue>39</issue>
<page-range>6058-68</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bittencourt]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Vertical transmission of HTLV-I/II: a review]]></article-title>
<source><![CDATA[Rev Inst Med Trop Sao Paulo]]></source>
<year>1998</year>
<month> J</month>
<day>ul</day>
<volume>40</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>245-51</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spalton]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Nicholson]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[HTLV-I infection in human disease]]></article-title>
<source><![CDATA[Br J Ophthalmol]]></source>
<year>1991</year>
<month> M</month>
<day>ar</day>
<volume>75</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>174-5</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Posada-Vergara]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Montanheiro]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Fukumori]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Bonasser]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Duarte]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Penalva de Oliveira]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Clinical and epidemiological aspects of HTLV-II infection in São Paulo, Brazil: presence of tropical spastic paraparesis/HTLV-associated myelopathy (TSP/HAM) simile diagnosis in HIV-1-co-infected subjects]]></article-title>
<source><![CDATA[Rev Inst Med Trop Sao Paulo]]></source>
<year>2006</year>
<month> J</month>
<day>ul</day>
<volume>48</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>207-10</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[FLN]]></given-names>
</name>
<name>
<surname><![CDATA[Lima]]></surname>
<given-names><![CDATA[FWM]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Epidemiologia, fisiopatogenia e diagnóstico laboratorial da infecção pelo HTLV-I]]></article-title>
<source><![CDATA[J Bras Patol Med Lab]]></source>
<year>2005</year>
<month> a</month>
<day>br</day>
<volume>41</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>105-16</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gonçalves]]></surname>
<given-names><![CDATA[DU]]></given-names>
</name>
<name>
<surname><![CDATA[Proietti]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[Ribas]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Araújo]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Pinheiro]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Guedes]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases]]></article-title>
<source><![CDATA[Clin Microbiol Rev]]></source>
<year>2010</year>
<month> J</month>
<day>ul</day>
<volume>23</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>577-89</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carneiro-Proietti]]></surname>
<given-names><![CDATA[ABF]]></given-names>
</name>
<name>
<surname><![CDATA[Ribas]]></surname>
<given-names><![CDATA[JGR]]></given-names>
</name>
<name>
<surname><![CDATA[Catalan-Soares]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
<name>
<surname><![CDATA[Martins]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Brito-Melo]]></surname>
<given-names><![CDATA[GEA]]></given-names>
</name>
<name>
<surname><![CDATA[Mertins-Filho]]></surname>
<given-names><![CDATA[AO]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Infecção e doença pelos vírus linfotrópicos humanos de células T (HTLV-I/II) no Brasil]]></article-title>
<source><![CDATA[Rev Soc Bras Med Trop]]></source>
<year>2002</year>
<month> s</month>
<day>et</day>
<volume>35</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>499-508</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Catalan-Soares]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Carneiro-Proietti]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Proietti]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Interdisciplinary HTLV Research Group: Heterogeneous geographic distribution of human T-cell lymphotropic viruses I and II (HTLV-I/II): serological screening prevalence rates in blood donors from large urban areas in Brazil]]></article-title>
<source><![CDATA[Cad Saude Publica]]></source>
<year>2005</year>
<month> M</month>
<day>ay</day>
<volume>21</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>926-31</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Igakura]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Stinchcombe]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Goon]]></surname>
<given-names><![CDATA[PKC]]></given-names>
</name>
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
<name>
<surname><![CDATA[Weber]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
<name>
<surname><![CDATA[Griffiths]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton]]></article-title>
<source><![CDATA[Science]]></source>
<year>2003</year>
<month> M</month>
<day>ar</day>
<volume>299</volume>
<numero>5613</numero>
<issue>5613</issue>
<page-range>1713-6</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tuke]]></surname>
<given-names><![CDATA[PW]]></given-names>
</name>
<name>
<surname><![CDATA[Luton]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Garson]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Differential diagnosis of HTLV-I and HTLV-II infections by restriction enzyme analysis of nested PCR productes]]></article-title>
<source><![CDATA[J Virol Methods]]></source>
<year>1992</year>
<month> N</month>
<day>ov</day>
<volume>40</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>163-74</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Greer]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Peterson]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Kiviat]]></surname>
<given-names><![CDATA[NB]]></given-names>
</name>
<name>
<surname><![CDATA[Manos]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[PCR amplification from paraffin-embedded tissues: effects of fixative and fixation time]]></article-title>
<source><![CDATA[Am J Clin Pathol]]></source>
<year>1991</year>
<month> F</month>
<day>eb</day>
<volume>95</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>117-24</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salles]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Sabino]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[Barreto]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Barreto]]></surname>
<given-names><![CDATA[AME]]></given-names>
</name>
<name>
<surname><![CDATA[Otani]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Chamone]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Descarte de bolsas de sangue e prevalência de doenças infecciosas em doadores de sangue da Fundação Pró-Sangue/Hemocentro de São Paulo]]></article-title>
<source><![CDATA[Rev Panam Salud Publica]]></source>
<year>2003</year>
<month> F</month>
<day>eb</day>
<volume>13</volume>
<numero>2-3</numero>
<issue>2-3</issue>
<page-range>111-6</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zehender]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Maddalena]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gianotto]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cavalli]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Santambrogio]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Orso]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[High prevalence of false-negative anti-HTLV type I/II enzyme-linked immunosorbent assay results in HIV type 1-positive patients]]></article-title>
<source><![CDATA[AIDS Res Hum Retroviruses]]></source>
<year>1997</year>
<month> S</month>
<day>ep</day>
<volume>13</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>1141-6</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caterino-de-Araujo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chieco-Bianchi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Meleiro]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Suleiman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Calabro]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Favero]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Sensitivity of two enzyme-linked immunosorbent assay tests in relation to western blot in detecting human T-cell lymphotropic virus types I and II infection among HIV-1 infected patients from São Paulo, Brazil]]></article-title>
<source><![CDATA[Diagn Microbiol Infect Dis]]></source>
<year>1998</year>
<month> M</month>
<day>ar</day>
<volume>30</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>173-82</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Poiesz]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Dube]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Esteban]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Leon­-Ponte]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Comparative performances of an HTLV-I/II EIA and other serologic and PCR assays on samples from persons at risk for HTLV-II infection]]></article-title>
<source><![CDATA[Transfusion]]></source>
<year>2000</year>
<month> A</month>
<day>ug</day>
<volume>40</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>924-30</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Britto]]></surname>
<given-names><![CDATA[APCR]]></given-names>
</name>
<name>
<surname><![CDATA[Galvão-Castro]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Straatmann]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Santos-Torres]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tavares-Neto]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Infecção pelo HTLV-I/II no Estado da Bahia]]></article-title>
<source><![CDATA[Rev Soc Bras Med Trop]]></source>
<year>1998</year>
<month> j</month>
<day>an</day>
<volume>31</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>35-41</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Colin]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
<name>
<surname><![CDATA[Alcântara Júnior]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
<name>
<surname><![CDATA[Uchôa]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Tavares-Neto]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Seroprevalence of human T cell lymphotropic virus infection and associated factors of risk in blood donors of Rio Branco city, AC, Brazil (1998-2001)]]></article-title>
<source><![CDATA[Rev Soc Bras Med Trop]]></source>
<year>2003</year>
<month> N</month>
<day>ov</day>
<volume>36</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>677-83</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Veit]]></surname>
<given-names><![CDATA[APT]]></given-names>
</name>
<name>
<surname><![CDATA[Mella]]></surname>
<given-names><![CDATA[EAC]]></given-names>
</name>
<name>
<surname><![CDATA[Mella-Junior]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Soroprevalência do vírus linfotrópico de células T humanas (HTLV-I/II) em indivíduos doadores de sangue do hemocentro da cidade de Maringá-PR]]></article-title>
<source><![CDATA[Arq Cienc Saude Unipar Umuarama]]></source>
<year>2006</year>
<month> s</month>
<day>et</day>
<volume>10</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>123-6</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lima]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Eustáquio]]></surname>
<given-names><![CDATA[JMJ]]></given-names>
</name>
<name>
<surname><![CDATA[Martins]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Josahkian]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Pereira]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Moraes-Souza]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Decline in the prevalence of HTLV-1/2 among blood donors at the Regional Blood Center of the City of Uberaba, State of Minas Gerais, from 1995 to 2008]]></article-title>
<source><![CDATA[Rev Soc Bras Med Trop]]></source>
<year>2010</year>
<month> J</month>
<day>ul</day>
<volume>43</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>421-4</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vallinoto]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Muto]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Pontes]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
<name>
<surname><![CDATA[Machado]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[Azevedo]]></surname>
<given-names><![CDATA[VN]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Serological and molecular evidence of HTLV-I infection among Japanese immigrants living in the Amazon region of Brazil]]></article-title>
<source><![CDATA[Jpn J Infect Dis]]></source>
<year>2004</year>
<month> A</month>
<day>ug</day>
<volume>57</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>156-9</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vallinoto]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Pontes]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
<name>
<surname><![CDATA[Muto]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Lopes]]></surname>
<given-names><![CDATA[IG]]></given-names>
</name>
<name>
<surname><![CDATA[Machado]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[Azevedo]]></surname>
<given-names><![CDATA[VN]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Identification of human T-cell lymphotropic virus infection in a semi-isolated Afro-Brazilian quilombo located in the Marajó Island (Pará, Brazil)]]></article-title>
<source><![CDATA[Mem Inst Oswaldo Cruz]]></source>
<year>2006</year>
<month> F</month>
<day>eb</day>
<volume>101</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>103-5</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ishak]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Harrington Jr]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Azevedo]]></surname>
<given-names><![CDATA[VN]]></given-names>
</name>
<name>
<surname><![CDATA[Eiraku]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ishak]]></surname>
<given-names><![CDATA[MO]]></given-names>
</name>
<name>
<surname><![CDATA[Guerreiro]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Identification of human T cell lymphotropic virus type IIa infection in the Kayapo, an indigenous population of Brazil]]></article-title>
<source><![CDATA[AIDS Res Hum Retroviruses]]></source>
<year>1995</year>
<month> J</month>
<day>ul</day>
<volume>11</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>813-21</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Catalan-Soares]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Carneiro-Proietti]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Proietti]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Grupo Interdisciplinar de Pesquisas em HTLV: Human T-cell lymphotropic virus in family members of seropositive blood donors: silent dissemination]]></article-title>
<source><![CDATA[Rev Panam Salud Publica]]></source>
<year>2004</year>
<month> D</month>
<day>ec</day>
<volume>16</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>387-94</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Wilks]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Morgan]]></surname>
<given-names><![CDATA[OS]]></given-names>
</name>
<name>
<surname><![CDATA[Hanchard]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Cranston]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Figueroa]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Health effects of human T-lymphotropic virus type I (HTLV-I) in a Jamaican cohort]]></article-title>
<source><![CDATA[Int J Epidemiol]]></source>
<year>1996</year>
<volume>25</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1090-7</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
